(Press-News.org) Contact information: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Study questions anti-cancer mechanisms of drug tested in clinical trials
CINCINNATI – The diabetes drug metformin is also being tested in numerous clinical trials for treating different cancers, and several studies point to its apparent activation of a molecular regulator of cell metabolism called AMPK to suppress tumor growth.
But new research appearing the week of Jan. 13 in Proceedings of the National Academy of Sciences (PNAS) suggests that activation of AMPK may actually fuel cancer growth. Researchers from Cincinnati Children's Hospital Medical Center who led the study also recommend that clinicians testing metformin for cancer treatment consider a careful re-evaluation of their clinical data.
The researchers report on extensive laboratory tests that conclude metformin does stop cancer, although not by activating AMPK. Instead, in tests involving glioma brain cancer cells, the authors found that metformin inhibits a different molecule called mammalian target of rapamycin (mTOR) that has been linked to many other cancers.
In the body, metformin also suppresses the actions of insulin and insulin-like growth factors – two molecules that support cancer growth – and also likely independent of AMPK, according to Biplab Dasgupta, PhD, principal investigator and a researcher in the Division of Hematology/Oncology at Cincinnati Children's.
"Our findings do not suggest that clinical trials using metformin should be stopped. Metformin appears to be a very useful drug, but the drug's mechanism of cancer suppression is not clear," Dr. Dasgupta said. "However, our findings unveil a potential role for AMPK as a tumor growth supporter, not a suppressor, in the type of cancer that we study. This is why clinicians using metformin in clinical trials should use caution during data interpretation."
Dasgupta and his research colleagues decided to tackle the question of metformin's anti-cancer properties because some studies point to AMPK as a tumor suppressor, while others have suggested it can promote tumor growth. Ultimately, an accurate understanding of AMPK's role – and how a drug like metformin does stop cancer – will likely be important to continued improvement of targeted cancer therapies, he said.
AMPK is a metabolic enzyme that acts as a key sensor of energy levels in cells. It controls a number of metabolic pathways that allow cells to regulate their energy usage and survival under physiological stress. Cancer cells modify their metabolism to maintain their growth and survival in the stressful environment of the tumor.
To determine how AMPK and metformin react in the context of cancer, the researchers conducted tests using glioblastoma, a highly lethal brain cancer with no cure. Their experiments involved laboratory cell cultures of human glioblastoma cells and glioblastoma tumors transplanted in mice to obtain results in a living organism.
Compared to normal human and mouse tissue, the researchers found that AMPK was highly active in human and mouse glioblastoma cells. This led them to question whether the anti-cancer properties of metformin were independent of AMPK, and instead directed to other molecular pathways.
The researchers then treated human glioblastoma cells with metformin and conducted a series of genetic tests to determine the molecular pathways it uses to stop the cancer growth. Those tests showed clearly that metformin directly inhibited the mTOR pathway (and the cancer) by promoting the interaction of two upstream molecules that stop the pathway's function.
To further verify that AMPK activation by metformin is not involved in stopping the growth of cancer, the researchers also treated the glioblastoma cells with a more specific AMPK activating compound called A769662 that directly binds to AMPK. The treatment did not kill glioblastoma cells, according to the authors.
Dasgupta and his colleagues are continuing their research by testing direct genetic inhibition of AMPK to see how it impacts human glioblastoma cells. Although that research still has to be completed and the results verified, he said preliminary indications are that blocking AMPK appears to kill a significant number of the glioblastoma cells.
###
The current study involved a collaboration of several scientists from Cincinnati Children's, including first co-author Xiaona Liu, MD, and Rishi Raj Chhipa, PhD, Division of Oncology. Other collaborating institutions included: the University of Cincinnati College of Medicine, the Mayfield Clinic, the Mayo Clinic, Katholieke Universiteit in Leuven, Belgium, Antwerp University Hospital in Belgium, the Inserm Institut Cochin and the Universite Paris Decartes, both in Paris, France.
Funding support for the study came from CancerFreeKids, the Smith-Brinker Golf Foundation, a Cincinnati Children's Trustee Scholar Grant and the National Institutes of Health (1RO1NS075291-01A1).
About Cincinnati Children's:
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2013 Best Children's Hospitals ranking. It is ranked #1 for cancer and in the top 10 for nine of 10 pediatric specialties. Cincinnati Children's, a non-profit organization, is one of the top three recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at http://www.cincinnatichildrens.org. Connect on the Cincinnati Children's blog, via Facebook and on Twitter.
Study questions anti-cancer mechanisms of drug tested in clinical trials
2014-01-14
ELSE PRESS RELEASES FROM THIS DATE:
NHS cancer risk threshold 'too high' for patients, research indicates
2014-01-14
NHS cancer risk threshold 'too high' for patients, research indicates
Patients have expressed an appetite for potential cancer symptoms to be checked out much sooner than current NHS thresholds guidelines suggest, new research has revealed.
A study ...
Chemical signaling simulates exercise in cartilage cells
2014-01-14
Chemical signaling simulates exercise in cartilage cells
DURHAM, N.C. -- Cartilage is notoriously difficult to repair or grow, but researchers at Duke Medicine have taken a step toward understanding how to regenerate the connective tissue. By ...
Most students exposed to school-based food commercialism
2014-01-14
Most students exposed to school-based food commercialism
Most students in elementary, middle and high schools are exposed to food commercialism (including exclusive beverage contracts and the associated incentives, profits and advertising) at school, although there ...
Study examines probiotic use in preventing gastrointestinal disorders in infants
2014-01-14
Study examines probiotic use in preventing gastrointestinal disorders in infants
Giving an infant a probiotic during the first three months of life appears to reduce the onset of gastrointestinal disorders and result in lower associated costs, according to a study ...
How fruit flies detect sweet foods
2014-01-14
How fruit flies detect sweet foods
UC Riverside research opens door for investigations into taste receptors of mosquitoes and other deadly insects
RIVERSIDE, Calif. — Insects represent remarkable diversity and have adapted to all sorts of ecological ...
Microbes buy low and sell high
2014-01-14
Microbes buy low and sell high
Microbes set up their own markets, comparing bids for commodities, hoarding to obtain a better price, and generally behaving in ways more commonly associated with Wall Street than the microscopic world
The idea that people make ...
New test could simplify the diagnosis of coeliac disease
2014-01-14
New test could simplify the diagnosis of coeliac disease
A new blood test being developed by Walter and Eliza Hall Institute researchers can rapidly and accurately diagnose coeliac disease without the need for prolonged gluten exposure.
Dr Jason Tye-Din, ...
More to biofuel production than yield
2014-01-14
More to biofuel production than yield
EAST LANSING, Mich. — When it comes to biofuels, corn leads the all-important category of biomass yield. However, focusing solely on yield comes at a high price.
In the current issue of the Proceedings for the National ...
How the immune system fights off malaria
2014-01-14
How the immune system fights off malaria
CAMBRIDGE, MA -- The parasites that cause malaria are exquisitely adapted to the various hosts they infect — so studying the disease in mice doesn't necessarily reveal information that could lead to drugs effective ...
Americans with and without children at home report similar life satisfaction but more positive and negative emotions
2014-01-14
Americans with and without children at home report similar life satisfaction but more positive and negative emotions
PRINCETON, N.J.—Americans aged 34 to 46 with children at home rate their life satisfaction ...